Therapix Biosciences (NSDQ:TRPX) said today that it inked a sublicense agreement for nasal drug delivery tech from Yissum Research Development Company at the Hebrew University. According to the deal, Yissum plans to give Therapix an exclusive, global, sub-licensable, royalty-bearing license for its nasal delivery tech to be used with cannabinoids. The technology was developed by […]
Neurological
Acorda to cut 20% of staff in restructuring effort
Acorda Therapeutics (NSDQ:ACOR) said today that it plans to cut 20% of its workforce as a part of a cost reduction and restructuring effort. The move comes less than 1 week after the company lost patents related to its multiple sclerosis drug, Ampyra. The Ardsley, N.Y.-based company had 597 employees as of February, according to Reuters, […]
Researchers mimic bee venom strategy to help drugs get past blood-brain barrier
Researchers from the Institute for Research in Biomedicine in Barcelona, Spain said yesterday that they have shown in preclinical tests that a bee-venom peptide, apamin, can be used to ferry medications across the blood-brain barrier. Although the blood-brain barrier prevents most things from getting in and flooding the brain, certain peptides in animal venoms can travel […]
Novocure touts long-term data for Optune, chemo combination therapy for glioblastoma
Shares in Novocure (NSDQ:NVCR) jumped nearly 50% today after the company touted 5-year data today from the Phase III pivotal EF-14 trial evaluating its Optune device with temozolomide chemotherapy as a treatment for newly-diagnosed glioblastoma. Data from 695 patients showed a consistent and maintained improvement in overall survival at 2, 3, 4 and 5 years, […]
Acorda plans NDA for inhaled Parkinson’s drug after touting long-term safety data
Acorda Therapeutics (NSDQ:ACOR) touted data from 2 ongoing, long-term safety studies of its inhaled Parkinson’s therapy. The trials showed no difference in pulmonary function between the group receiving CVT-301, the inhaled formulation of Parkinson’s drug levodopa, and the control group. The investigational drug is being studied as a therapy for people with Parkinson’s disease experiencing “off” […]
Longeveron finishes enrollment in stem cell trial for Alzheimer’s disease
Longeveron said today that it finished enrollment for the 1st phase of its human mesenchymal stem cell trial for Alzheimer’s disease. The company enrolled and infused 5 patients to collect safety data for its exogenously administered mesenchymal stem cells derived from adult donors’ bone marrow. After reviewing safety data, Longeveron said it plans to enroll 25 […]
Prometra micro-infusion device used to deliver meds directly to brain in epilepsy trial
Flowonix Medical and Cerebral Therapeutics said today that the 1st patients were implanted with the Prometra II programmable infusion system in a clinical trial evaluating the pump in patients with refractory epilepsy. The Address trial marks the 1st time a programmable, implantable pump has been used to deliver medication, in this case valproate, directly to […]
Cerveau Technologies, Wisconsin Alzheimer’s Center ink research deal
Cerveau Technologies said today that it landed a clinical research agreement with the University of Wisconsin-Madison Alzheimer’s Research Center to study an early stage imaging agent with positron emission tomography scans to assess the status and progression of neurofibrillary tangles in the brain. Neurofibrillary tangles composed of tau protein are characteristic of certain neurodegenerative diseases, […]
Study: Localized delivery of chemo improves prognosis of recurrent glioblastoma
Researchers from Amrita University in India demonstrated that localized and sustained delivery of a chemotherapeutic agent in brain tumors can improve the prognosis of recurrent glioblastoma. The team’s work was published in Scientific Reports. Although new drugs have been developed for glioblastoma multiforme, the overall survival rate for patients remains dismally low at 12 months, with […]
FDA asks Titan for more info before clinical trial of ropinirole implant
Titan Pharmaceuticals (NSDQ:TTNP) said today that the FDA put a hold on the clinical trial of its ropinirole implant and told the company to submit more information to the federal watchdog. After it completed an initial review of the implant’s Investigational New Drug application, the FDA asked Titan for final release test data on its ropinirole […]